The Banff 2015 Kidney Meeting Report: Current Challenges in Rejection Classification and Prospects for Adopting Molecular Pathology

A Loupy, M Haas, K Solez, L Racusen, D Glotz, D Seron, B J Nankivell, R B Colvin, M Afrouzian, E Akalin, N Alachkar, S Bagnasco, J U Becker, L Cornell, C Drachenberg, D Dragun, H de Kort, I W Gibson, E S Kraus, C Lefaucheur, C Legendre, H Liapis, T Muthukumar, V Nickeleit, B Orandi, W Park, M Rabant, P Randhawa, E F Reed, C Roufosse, S V Seshan, B Sis, H K Singh, C Schinstock, A Tambur, A Zeevi, M Mengel, A Loupy, M Haas, K Solez, L Racusen, D Glotz, D Seron, B J Nankivell, R B Colvin, M Afrouzian, E Akalin, N Alachkar, S Bagnasco, J U Becker, L Cornell, C Drachenberg, D Dragun, H de Kort, I W Gibson, E S Kraus, C Lefaucheur, C Legendre, H Liapis, T Muthukumar, V Nickeleit, B Orandi, W Park, M Rabant, P Randhawa, E F Reed, C Roufosse, S V Seshan, B Sis, H K Singh, C Schinstock, A Tambur, A Zeevi, M Mengel

Abstract

The XIII Banff meeting, held in conjunction the Canadian Society of Transplantation in Vancouver, Canada, reviewed the clinical impact of updates of C4d-negative antibody-mediated rejection (ABMR) from the 2013 meeting, reports from active Banff Working Groups, the relationships of donor-specific antibody tests (anti-HLA and non-HLA) with transplant histopathology, and questions of molecular transplant diagnostics. The use of transcriptome gene sets, their resultant diagnostic classifiers, or common key genes to supplement the diagnosis and classification of rejection requires further consensus agreement and validation in biopsies. Newly introduced concepts include the i-IFTA score, comprising inflammation within areas of fibrosis and atrophy and acceptance of transplant arteriolopathy within the descriptions of chronic active T cell-mediated rejection (TCMR) or chronic ABMR. The pattern of mixed TCMR and ABMR was increasingly recognized. This report also includes improved definitions of TCMR and ABMR in pancreas transplants with specification of vascular lesions and prospects for defining a vascularized composite allograft rejection classification. The goal of the Banff process is ongoing integration of advances in histologic, serologic, and molecular diagnostic techniques to produce a consensus-based reporting system that offers precise composite scores, accurate routine diagnostics, and applicability to next-generation clinical trials.

Keywords: clinical research/practice; kidney transplantation/nephrology; organ transplantation in general; pathology/histopathology; rejection; rejection: T cell mediated (TCMR); rejection: antibody-mediated (ABMR); rejection: subclinical; translational research/science.

© 2016 The Authors. American Journal of Transplantation published by Wiley Periodicals, Inc. on behalf of American Society of Transplant Surgeons.

Figures

Figure 1
Figure 1
Molecular lesions and their corresponding histologic lesions in T cell–mediated rejection and antibody‐mediated rejection in kidney allografts. cg, glomerular double contours; cv, vascular fibrous intimal thickening; i, inflammation; ptc, peritubular capillaritis; ti, total inflammation; v, intimal arteritis.

References

    1. Haas M, Sis B, Racusen LC, et al. Banff 2013 meeting report: Inclusion of c4d‐negative antibody‐mediated rejection and antibody‐associated arterial lesions. Am J Transplant 2014; 14: 272–283.
    1. Sis B, Mengel M, Haas M, et al. Banff ‘09 meeting report: Antibody mediated graft deterioration and implementation of Banff working groups. Am J Transplant 2010; 10: 464–471.
    1. Sis B, Bagnasco SM, Cornell LD, et al. Isolated endarteritis and kidney transplant survival: A multicenter collaborative study. J Am Soc Nephrol 2015; 26: 1216–1227.
    1. Mengel M, Chan S, Climenhaga J, et al. Banff initiative for quality assurance in transplantation (BIFQUIT): Reproducibility of C4d immunohistochemistry in kidney allografts. Am J Transplant 2013; 13: 1235–1245.
    1. Farris AB, Chan S, Climenhaga J, et al. Banff fibrosis study: Multicenter visual assessment and computerized analysis of interstitial fibrosis in kidney biopsies. Am J Transplant 2014; 14: 897–907.
    1. Liapis H, Gaut JP, Klein C, et al. Banff histopathological consensus criteria for pre‐implantation kidney biopsies. Am J Transplant 2016. [Epub ahead of print]
    1. Adam B, Randhawa P, Chan S, et al. Banff Initiative for Quality Assurance in Transplantation (BIFQUIT): Reproducibility of polyomavirus immunohistochemistry in kidney allografts. Am J Transplant 2014; 14: 2137–2147.
    1. Solez K. Multibiomarker article gives a taste of what the era of regenerative medicine/tissue engineering pathology will be like. Crit Care Med 2015; 43: e599–e600.
    1. Wiebe C, Gibson IW, Blydt‐Hansen TD, et al. Rates and determinants of progression to graft failure in kidney allograft recipients with de novo donor‐specific antibody. Am J Transplant 2015; 15: 2921–2930.
    1. Orandi BJ, Luo X, Massie AB, et al. Survival benefit with kidney transplants from hla‐incompatible live donors. N Engl J Med 2016; 374: 940–950.
    1. Loupy A, Vernerey D, Tinel C, et al. Subclinical rejection phenotypes at 1 year post‐transplant and outcome of kidney allografts. J Am Soc Nephrol 2015; 26: 1721–1731.
    1. Tait BD, Susal C, Gebel HM, et al. Consensus guidelines on the testing and clinical management issues associated with HLA and non‐HLA antibodies in transplantation. Transplantation 2013; 95: 19–47.
    1. Chen G, Sequeira F, Tyan DB. Novel C1q assay reveals a clinically relevant subset of human leukocyte antigen antibodies independent of immunoglobulin G strength on single antigen beads. Hum Immunol 2011; 72: 849–858.
    1. Yabu JM, Higgins JP, Chen G, Sequeira F, Busque S, Tyan DB. C1q‐fixing human leukocyte antigen antibodies are specific for predicting transplant glomerulopathy and late graft failure after kidney transplantation. Transplantation 2011; 91: 342–347.
    1. Loupy A, Lefaucheur C, Vernerey D, et al. Complement‐binding anti‐HLA antibodies and kidney‐allograft survival. N Engl J Med 2013; 369: 1215–1226.
    1. Sicard A, Ducreux S, Rabeyrin M, et al. Detection of C3d‐binding donor‐specific anti‐HLA antibodies at diagnosis of humoral rejection predicts renal graft loss. J Am Soc Nephrol 2015; 26: 457–467.
    1. Susal C, Wettstein D, Dohler B, et al. Association of kidney graft loss with de novo produced donor‐specific and non‐donor‐specific HLA antibodies detected by single antigen testing. Transplantation 2015; 99: 1976–1980.
    1. Yamamoto T, Watarai Y, Takeda A, et al. De novo anti‐HLA DSA characteristics and subclinical antibody‐mediated kidney allograft injury. Transplantation 2015. [Epub ahead of print]
    1. Fichtner A, Susal C, Hocker B, et al. Association of C1q‐fixing DSA with late graft failure in pediatric renal transplant recipients. Pediatr Nephrol 2016; 31: 1157–1166.
    1. Bamoulid J, Roodenburg A, Staeck O, et al. Clinical outcome of patients with de novo C1q‐binding donor‐specific HLA antibodies after renal transplantation. Transplantation 2016. [Epub ahead of print]
    1. O'Leary JG, Kaneku H, Banuelos N, Jennings LW, Klintmalm GB, Terasaki PI. Impact of IgG3 subclass and C1q‐fixing donor‐specific HLA alloantibodies on rejection and survival in liver transplantation. Am J Transplant 2015; 15: 1003–1013.
    1. Zeevi A, Lunz J, Feingold B, et al. Persistent strong anti‐HLA antibody at high titer is complement binding and associated with increased risk of antibody‐mediated rejection in heart transplant recipients. J Heart Lung Transplant 2013; 32: 98–105.
    1. Tambur AR, Herrera ND, Haarberg KM, et al. Assessing antibody strength: Comparison of MFI, C1q, and titer information. Am J Transplant 2015; 15: 2421–2430.
    1. Lefaucheur C, Viglietti D, Bentlejewski C, et al. IgG donor‐specific anti‐human HLA antibody subclasses and kidney allograft antibody‐mediated injury. J Am Soc Nephrol 2016; 27: 293–304.
    1. Calp‐Inal S, Ajaimy M, Melamed ML, et al. The prevalence and clinical significance of C1q‐binding donor‐specific anti‐HLA antibodies early and late after kidney transplantation. Kidney Int 2016; 89: 209–216.
    1. Dragun D, Muller DN, Brasen JH, et al. Angiotensin II type 1‐receptor activating antibodies in renal‐allograft rejection. N Engl J Med 2005; 352: 558–569.
    1. Reinsmoen NL, Lai CH, Mirocha J, et al. Increased negative impact of donor HLA‐specific together with non‐HLA‐specific antibodies on graft outcome. Transplantation 2014; 97: 595–601.
    1. Zhang Q, Reed EF. The importance of non‐HLA antibodies in transplantation. Nat Rev Nephrol 2016; 12: 484–495.
    1. Hidalgo LG, Sis B, Sellares J, et al. NK cell transcripts and NK cells in kidney biopsies from patients with donor‐specific antibodies: Evidence for NK cell involvement in antibody‐mediated rejection. Am J Transplant 2010; 10: 1812–1822.
    1. Gupta A, Broin PO, Bao Y, et al. Clinical and molecular significance of microvascular inflammation in transplant kidney biopsies. Kidney Int 2016; 89: 217–225.
    1. Nickeleit V, Zeiler M, Gudat F, Thiel G, Mihatsch MJ. Detection of the complement degradation product C4d in renal allografts: Diagnostic and therapeutic implications. J Am Soc Nephrol 2002; 13: 242–251.
    1. Lefaucheur C, Loupy A, Vernerey D, et al. Antibody‐mediated vascular rejection of kidney allografts: A population‐based study. Lancet 2013; 381: 313–319.
    1. Haas M, Kraus ES, Samaniego‐Picota M, Racusen LC, Ni W, Eustace JA. Acute renal allograft rejection with intimal arteritis: Histologic predictors of response to therapy and graft survival. Kidney Int 2002; 61: 1516–1526.
    1. Sellares J, de Freitas DG, Mengel M, et al. Understanding the causes of kidney transplant failure: The dominant role of antibody‐mediated rejection and nonadherence. Am J Transplant 2012; 12: 388–399.
    1. Kahwaji J, Najjar R, Kancherla D, et al. Histopathologic features of transplant glomerulopathy associated with response to therapy with intravenous immune globulin and rituximab. Clin Transplant 2014; 28: 546–553.
    1. Kulkarni S, Kirkiles‐Smith NC, Deng YH, et al. Eculizumab therapy for chronic antibody‐mediated injury in kidney transplant recipients: A pilot randomized controlled trial. Am J Transplant 2016. [Epub ahead of print]
    1. Lesage J, Noel R, Lapointe I, et al. Donor‐specific antibodies, C4d and their relationship with the prognosis of transplant glomerulopathy. Transplantation 2015; 99: 69–76.
    1. Solez K, Colvin RB, Racusen LC, et al. Banff 07 classification of renal allograft pathology: Updates and future directions. Am J Transplant 2008; 8: 753–760.
    1. Mengel M, Reeve J, Bunnag S, et al. Scoring total inflammation is superior to the current Banff inflammation score in predicting outcome and the degree of molecular disturbance in renal allografts. Am J Transplant 2009; 9: 1859–1867.
    1. Mannon RB, Matas AJ, Grande J, et al. Inflammation in areas of tubular atrophy in kidney allograft biopsies: A potent predictor of allograft failure. Am J Transplant 2010; 10: 2066–2073.
    1. Hueso M, Navarro E, Moreso F, et al. Intragraft expression of the IL‐10 gene is up‐regulated in renal protocol biopsies with early interstitial fibrosis, tubular atrophy, and subclinical rejection. Am J Pathol 2010; 176: 1696–1704.
    1. Loupy A, Vernerey D, Viglietti D, et al. Determinants and outcomes of accelerated arteriosclerosis: Major impact of circulating antibodies. Circ Res 2015; 117: 470–482.
    1. Hirohashi T, Uehara S, Chase CM, et al. Complement independent antibody‐mediated endarteritis and transplant arteriopathy in mice. Am J Transplant 2010; 10: 510–517.
    1. Sarwal M, Sigdel T. A common blood gene assay predates clinical and histological rejection in kidney and heart allografts. Clin Transpl 2013: 241–247.
    1. Muthukumar T, Lee JR, Dadhania DM, et al. Allograft rejection and tubulointerstitial fibrosis in human kidney allografts: Interrogation by urinary cell mRNA profiling. Transplant Rev 2014; 28: 145–154.
    1. Halloran PF, de Freitas DG, Einecke G, et al. An integrated view of molecular changes, histopathology and outcomes in kidney transplants. Am J Transplant 2010; 10: 2223–2230.
    1. Halloran PF, Pereira AB, Chang J, et al. Potential impact of microarray diagnosis of T cell‐mediated rejection in kidney transplants: The INTERCOM study. Am J Transplant 2013; 13: 2352–2363.
    1. Halloran PF, Pereira AB, Chang J, et al. Microarray diagnosis of antibody‐mediated rejection in kidney transplant biopsies: An international prospective study (INTERCOM). Am J Transplant 2013; 13: 2865–2874.
    1. Halloran PF, Reeve JP, Pereira AB, Hidalgo LG, Famulski KS. Antibody‐mediated rejection, T cell‐mediated rejection, and the injury‐repair response: New insights from the Genome Canada studies of kidney transplant biopsies. Kidney Int 2014; 85: 258–264.
    1. Loupy A, Lefaucheur C, Vernerey D, et al. Molecular microscope strategy to improve risk stratification in early antibody‐mediated kidney allograft rejection. J Am Soc Nephrol 2014; 25: 2267–2277.
    1. Li L, Khush K, Hsieh SC, et al. Identification of common blood gene signatures for the diagnosis of renal and cardiac acute allograft rejection. PLoS ONE 2013; 8: e82153.
    1. Khatri P, Roedder S, Kimura N, et al. A common rejection module (CRM) for acute rejection across multiple organs identifies novel therapeutics for organ transplantation. J Exp Med 2013; 210: 2205–2221.
    1. Halloran PF, Famulski KS, Reeve J. Molecular assessment of disease states in kidney transplant biopsy samples. Nat Rev Nephrol 2016; 12: 534–548.
    1. Sis B, Jhangri GS, Bunnag S, Allanach K, Kaplan B, Halloran PF. Endothelial gene expression in kidney transplants with alloantibody indicates antibody‐mediated damage despite lack of C4d staining. Am J Transplant 2009; 9: 2312–2323.
    1. Hayde N, Broin PO, Bao Y, et al. Increased intragraft rejection‐associated gene transcripts in patients with donor‐specific antibodies and normal biopsies. Kidney Int 2014; 86: 600–609.
    1. Halloran PF, Famulski K, Reeve J. The molecular phenotypes of rejection in kidney transplant biopsies. Curr Opin Organ Transplant 2015; 20: 359–367.
    1. Troxell ML, Drachenberg C. Allograft pancreas: Pale acinar nodules. Hum Pathol 2016; 54: 127–133.
    1. Chandraker A, Arscott R, Murphy GF, et al. The management of antibody‐mediated rejection in the first presensitized recipient of a full‐face allotransplant. Am J Transplant 2014; 14: 1446–1452.
    1. Kanitakis J, Petruzzo P, Gazarian A, et al. Capillary thrombosis in the skin: A pathologic hallmark of severe/chronic rejection of human vascularized composite tissue allografts? Transplantation 2016; 100: 954–957.
    1. Drachenberg CB, Torrealba JR, Nankivell BJ, et al. Guidelines for the diagnosis of antibody‐mediated rejection in pancreas allografts—Updated Banff grading schema. Am J Transplant 2011; 11: 1792–1802.
    1. Drachenberg CB, Odorico J, Demetris AJ, et al. Banff schema for grading pancreas allograft rejection: Working proposal by a multi‐disciplinary international consensus panel. Am J Transplant 2008; 8: 1237–1249.

Source: PubMed

Sponsors en medewerkers

Medische omstandigheden

Geneesmiddelinterventies

3
Abonneren